Angiodynamics Inc (ANGO)

$12.34 +0.34 (2.83%)
Market Cap 494.40M
Revenue (ttm) 292.50M
Net Income (ttm) -33.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.62%
Debt to Equity Ratio 0.00
Volume 632,900
Avg Vol 494,596
Day's Range N/A - N/A
Shares Out 41.20M
Stochastic %K 92%
Beta 0.78
Analysts Strong Sell
Price Target $19.33

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 518 795 1400
Address:
14 Plaza Drive, Latham, United States
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:23 PM
$ANEW $ANF $ANGO $ANIP $ANRO
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:50 PM
$ANGO $ANIP $ANRO 🔥 Cycle Trading Signal plugged into AI 🔥 You lie they lie but Math don't lie 🔥 keep counting 😉
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 23 at 4:56 PM
$ANGO Outstanding article that hits the mark on ANGO's current state. So if you want to refresh your ANGO insights or learn about ANGO from scratch, this is a must read. https://beyondspx.com/quote/ANGO/analysis/angiodynamics-medtech-momentum-fuels-profitable-growth-trajectory-nasdaq-ango
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 22 at 8:21 PM
$ANGO 📰Another insider buy on $ANGO SVP, Chief Legal Officer buys 10,000 shares worth $118,100 https://x.com/sexystockslayer/status/1980982792126382519?s=46&t=5HwCsAVewgyd7U6TGAcZ8w
0 · Reply
SocioCobb
SocioCobb Oct. 22 at 3:33 PM
$ANGO
0 · Reply
SuperCoach
SuperCoach Oct. 16 at 12:45 PM
$ANGO https://time.com/collections/best-inventions-2025/7318433/angiodynamics-nanoknife/
0 · Reply
SuperCoach
SuperCoach Oct. 16 at 12:41 PM
$ANGO 😃👍🏻
0 · Reply
resistancebreakers
resistancebreakers Oct. 16 at 12:22 PM
$DTIL $ANGO 🖥️🪖🫡☝️
0 · Reply
G101SPM
G101SPM Oct. 14 at 4:33 PM
#INSIDERS $ANGO Chief Financial Officer bought 890 shares at $11.16 worth approximately $10K. $ZBIO Director bought 117,255 shares at $19.00 - $20.85 worth approximately $2.X.3 mln pursuant to Securities Purchase Agreement. $CRWV 10% owner Magnetar Financial sold another 414,547 shares of Class A Common Stock worth approximately $61.7 mln
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 13 at 10:45 PM
$ANGO SWING IDEA • Consistent earnings beats since Q4 2024 • 4th consecutive Q of over 20% revenue growth • CEO bought $110,000 in shares • AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List • Net Sales, EBITDA, EPS increased • Cashflow positive 2026 https://x.com/SexyStockSlayer/status/1977863102398943369
0 · Reply
Latest News on ANGO
AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

Oct 13, 2025, 8:30 AM EDT - 12 days ago

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

Oct 2, 2025, 3:00 PM EDT - 23 days ago

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Oct 2, 2025, 10:02 AM EDT - 23 days ago

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

Oct 2, 2025, 9:44 AM EDT - 23 days ago

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Oct 2, 2025, 6:00 AM EDT - 23 days ago

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

Oct 1, 2025, 9:57 AM EDT - 24 days ago

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

Sep 18, 2025, 8:00 AM EDT - 5 weeks ago

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

Aug 17, 2025, 8:23 AM EDT - 2 months ago

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 2 months ago

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Jul 28, 2025, 8:30 AM EDT - 3 months ago

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Jul 23, 2025, 8:30 AM EDT - 3 months ago

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 12:40 PM EDT - 3 months ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 11:59 AM EDT - 3 months ago

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Jul 15, 2025, 6:30 AM EDT - 3 months ago

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

Jul 7, 2025, 8:00 AM EDT - 3 months ago

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Jun 23, 2025, 8:00 AM EDT - 4 months ago

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

Apr 2, 2025, 10:41 AM EDT - 7 months ago

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 10:20 AM EDT - 7 months ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

Apr 2, 2025, 6:30 AM EDT - 7 months ago

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 31, 2025, 8:00 AM EDT - 7 months ago

AngioDynamics to Host Virtual Cardiovascular Investor Event

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Mar 19, 2025, 8:00 AM EDT - 7 months ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

Mar 10, 2025, 4:30 PM EDT - 8 months ago

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Jan 30, 2025, 7:30 AM EST - 9 months ago

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

Jan 16, 2025, 5:07 AM EST - 10 months ago

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Jan 13, 2025, 8:00 AM EST - 10 months ago

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 5:15 PM EST - 10 months ago

AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 11:00 AM EST - 10 months ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Jan 8, 2025, 6:30 AM EST - 10 months ago

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:26 AM EST - 10 months ago

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

Jan 6, 2025, 9:25 AM EST - 10 months ago

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Dec 19, 2024, 5:00 PM EST - 11 months ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

Dec 9, 2024, 6:00 AM EST - 11 months ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

Oct 23, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

Oct 21, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Oct 3, 2024, 10:29 AM EDT - 1 year ago

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

Oct 3, 2024, 10:02 AM EDT - 1 year ago

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

LEVI NGVT

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Oct 3, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

Oct 3, 2024, 3:37 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Sep 19, 2024, 4:40 PM EDT - 1 year ago

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

Sep 19, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

Sep 3, 2024, 8:30 AM EDT - 1 year ago

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

AngioDynamics to Participate in Upcoming Investor Conferences

Jul 29, 2024, 4:15 PM EDT - 1 year ago

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics: Lumpy Progress Is Still Progress

Jul 17, 2024, 3:16 PM EDT - 1 year ago

AngioDynamics: Lumpy Progress Is Still Progress

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

Jul 16, 2024, 1:51 PM EDT - 1 year ago

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

Jul 16, 2024, 10:35 AM EDT - 1 year ago

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

Jul 16, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

Jul 8, 2024, 4:30 PM EDT - 1 year ago

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

May 21, 2024, 5:30 PM EDT - 1 year ago

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

May 6, 2024, 4:45 PM EDT - 1 year ago

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 9, 2024, 4:49 PM EDT - 1 year ago

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:23 PM
$ANEW $ANF $ANGO $ANIP $ANRO
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:50 PM
$ANGO $ANIP $ANRO 🔥 Cycle Trading Signal plugged into AI 🔥 You lie they lie but Math don't lie 🔥 keep counting 😉
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 23 at 4:56 PM
$ANGO Outstanding article that hits the mark on ANGO's current state. So if you want to refresh your ANGO insights or learn about ANGO from scratch, this is a must read. https://beyondspx.com/quote/ANGO/analysis/angiodynamics-medtech-momentum-fuels-profitable-growth-trajectory-nasdaq-ango
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 22 at 8:21 PM
$ANGO 📰Another insider buy on $ANGO SVP, Chief Legal Officer buys 10,000 shares worth $118,100 https://x.com/sexystockslayer/status/1980982792126382519?s=46&t=5HwCsAVewgyd7U6TGAcZ8w
0 · Reply
SocioCobb
SocioCobb Oct. 22 at 3:33 PM
$ANGO
0 · Reply
SuperCoach
SuperCoach Oct. 16 at 12:45 PM
$ANGO https://time.com/collections/best-inventions-2025/7318433/angiodynamics-nanoknife/
0 · Reply
SuperCoach
SuperCoach Oct. 16 at 12:41 PM
$ANGO 😃👍🏻
0 · Reply
resistancebreakers
resistancebreakers Oct. 16 at 12:22 PM
$DTIL $ANGO 🖥️🪖🫡☝️
0 · Reply
G101SPM
G101SPM Oct. 14 at 4:33 PM
#INSIDERS $ANGO Chief Financial Officer bought 890 shares at $11.16 worth approximately $10K. $ZBIO Director bought 117,255 shares at $19.00 - $20.85 worth approximately $2.X.3 mln pursuant to Securities Purchase Agreement. $CRWV 10% owner Magnetar Financial sold another 414,547 shares of Class A Common Stock worth approximately $61.7 mln
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 13 at 10:45 PM
$ANGO SWING IDEA • Consistent earnings beats since Q4 2024 • 4th consecutive Q of over 20% revenue growth • CEO bought $110,000 in shares • AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List • Net Sales, EBITDA, EPS increased • Cashflow positive 2026 https://x.com/SexyStockSlayer/status/1977863102398943369
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 13 at 10:17 PM
$ANGO in at 11.39 DD soon
0 · Reply
SEC_official_Account
SEC_official_Account Oct. 12 at 10:11 PM
$ANGO Gamble 9
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Oct. 10 at 3:15 AM
$ANGO CEO purchased 10,000 shares at $11.15 for a total of $111,500. Clemmer James C now owns 882,529 shares. https://ceo-buys.com
0 · Reply
momyurich
momyurich Oct. 9 at 6:01 PM
$ANGO 📈
0 · Reply
Jigajack1
Jigajack1 Oct. 9 at 12:55 PM
$ANGO strong pre market, hit the support ready for a run at $13.50
0 · Reply
PivotW0lf
PivotW0lf Oct. 6 at 6:20 PM
$ANGO Keep refreshing. NXXT isn’t done yet. It’s just getting cocky. 🦍
0 · Reply
momyurich
momyurich Oct. 6 at 5:36 PM
$ANGO 📈
0 · Reply
Estimize
Estimize Oct. 6 at 2:03 PM
Wall St is expecting -0.10 EPS for $ANGO Q2 [Reporting 01/01 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
DARKP00L
DARKP00L Oct. 3 at 2:21 PM
$ANGO 10:01 on Oct. 03 2025 Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $18 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 2:01 PM
Canaccord Genuity updates rating for AngioDynamics ( $ANGO ) to Buy, target set at 17 → 18.
0 · Reply
ZacksResearch
ZacksResearch Oct. 3 at 12:27 PM
$ANGO posts a narrower-than-expected loss — bullish signs ahead? 🔍 💰 Adjusted loss per share of 10 cents beat the Zacks Consensus Estimate of 14 cents. 📈 Pro-forma revenue jumped 12.2% on a reported basis, with Med Tech sales increasing 26%. Discover what this means for ANGO's FY26 outlook here 👉 https://www.zacks.com/stock/news/2761304/ango-stock-gains-following-q1-earnings-beat-gross-margin-improves?cid=sm-stocktwits-2-2761304-body-14575&ADID=SYND_STOCKTWITS_TWEET_2_2761304_BODY_14575
0 · Reply
ZacksResearch
ZacksResearch Oct. 3 at 11:27 AM
$ANGO pops after Q1 surprise 🚀 Narrower-than-expected loss, 12% revenue growth, and improved margins — plus a raised FY26 sales outlook — lit a fire under the stock. Full breakdown here 👉 https://www.zacks.com/stock/news/2761304/ango-stock-gains-following-q1-earnings-beat-gross-margin-improves?cid=sm-stocktwits-2-2761304-teaser-14574&ADID=SYND_STOCKTWITS_TWEET_2_2761304_TEASER_14574
0 · Reply